Drug Trial Radar · NCT01802333
Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia
Last checked: Nov 20, 2026Latest source record: Dec 19, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
754
Actual
Start
Feb 12, 2013
Primary completion
Jun 15, 2017
Study completion Jun 15, 2017
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Mar 1, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomized phase III trial studies cytarabine and daunorubicin hydrochloride or idarubicin and cytarabine with or without vorinostat to see how well they work in treating younger patients with previously untreated acute myeloid leukemia. Drugs used in chemotherapy, such as cytarabine, daunorubicin hydrochloride, idarubicin, and vorinostat, work in different ways to stop the growth of cancer cells, either by killing the cells, stopping them from dividing, or by stopping from spreading. Giving more than one drug (combination chemotherapy) and giving the drugs in different doses and in different combinations may kill more cancer cells. It is not yet known which combination chemotherapy is more effective in treating acute myeloid leukemia.
Conditions
- Acute Myeloid Leukemia
- Untreated Adult Acute Myeloid Leukemia
Interventions
Allogeneic Hematopoietic Stem Cell TransplantationProcedure
Undergo allogeneic transplant
CytarabineDrug
Given IV
Daunorubicin HydrochlorideDrug
Given IV
IdarubicinDrug
Given IV
Laboratory Biomarker AnalysisOther
Correlative studies
VorinostatDrug
Given PO
Primary outcomes
What the sponsor says the trial is designed to measure.
- Event-free Survival (EFS)Time frame: EFS assessed for up to 5 years, 2 year EFS reported
- Rate of Allogeneic HCTTime frame: Up to 5 years
Locations
447 sites in 2 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama
Anchorage Radiation Therapy Center
Anchorage, Alaska
Alaska Breast Care and Surgery LLC
Anchorage, Alaska
Alaska Oncology and Hematology LLC
Anchorage, Alaska
Alaska Regional Hospital
Anchorage, Alaska
Alaska Women's Cancer Care
Anchorage, Alaska
Anchorage Oncology Centre
Anchorage, Alaska
Katmai Oncology Group
Anchorage, Alaska
Providence Alaska Medical Center
Anchorage, Alaska
University of Arizona Cancer Center-Orange Grove Campus
Tucson, Arizona
University of Arizona Cancer Center-North Campus
Tucson, Arizona
The University of Arizona Medical Center-University Campus
Tucson, Arizona
Yuma Cancer Center
Yuma, Arizona
Mercy Cancer Center-Hot Springs
Hot Springs, Arkansas
Providence Saint Joseph Medical Center/Disney Family Cancer Center
Burbank, California
City of Hope Comprehensive Cancer Center
Duarte, California
UC San Diego Moores Cancer Center
La Jolla, California
Fremont - Rideout Cancer Center
Marysville, California
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California
Stanford Cancer Institute Palo Alto
Palo Alto, California
University of California Davis Comprehensive Cancer Center
Sacramento, California
Poudre Valley Hospital
Fort Collins, Colorado
Hartford Hospital
Hartford, Connecticut
Smilow Cancer Hospital Care Center at Saint Francis
Hartford, Connecticut
Yale University
New Haven, Connecticut
University of Florida Health Science Center - Gainesville
Gainesville, Florida
Moffitt Cancer Center
Tampa, Florida
Northside Hospital
Atlanta, Georgia
Northside Hospital-Forsyth
Cumming, Georgia
Saint Alphonsus Cancer Care Center-Boise
Boise, Idaho
Saint Luke's Mountain States Tumor Institute
Boise, Idaho
Kootenai Medical Center
Coeur d'Alene, Idaho
Saint Luke's Mountain States Tumor Institute - Fruitland
Fruitland, Idaho
Saint Luke's Mountain States Tumor Institute - Meridian
Meridian, Idaho
Saint Luke's Mountain States Tumor Institute - Nampa
Nampa, Idaho
Kootenai Cancer Center
Post Falls, Idaho
Kootenai Cancer Clinic
Sandpoint, Idaho
Saint Luke's Mountain States Tumor Institute-Twin Falls
Twin Falls, Idaho
Saint Joseph Medical Center
Bloomington, Illinois
Illinois CancerCare-Bloomington
Bloomington, Illinois
Showing 40 of 447 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.